Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

per share from discontinued operations $- $(0.01) Net loss per share $(0.12) $(0.13)

                           SELECTED BALANCE SHEET DATA
                                 (in thousands)

                                             As of March 31,   As of December
                                                 2009              31, 2008
                                              (unaudited)
    Cash and cash equivalents                   $19,629            $26,938
    Short-term investments                        5,958              6,962
    Total current assets                         26,642             35,096
    Working capital                                (190)             7,379
    Total assets                                 67,962             76,625
    Long term debt                                  468                480
    Stockholders' equity                         37,794             76,625


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s resolutions ... care of my furry companion." Nowadays there are pet salons, dog ... to take the little canine or feline darlings along wherever mommy ... some pricey toys at the pet store. But anyone who has ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... May 24 SyntheMed, Inc. (OTC Bulletin ... and commercialization of anti-adhesion products, today announced that REPEL-GYN™, ... of adhesions following gynecologic surgery, has received CE Mark ... signifies that REPEL-GYN has met the essential requirements of ...
... Mass. , May 24 Repligen Corporation (Nasdaq: ... Products Development of the Food and Drug Administration (FDA) has ... 3 (HDAC-3) inhibitor for the treatment of Friedreich,s ataxia.  Orphan ... exclusivity in the United States if the company ...
... CARLSBAD, Calif. ; May 24 MO ... microbial nucleic acid purification, announces the launch of a ... for powerful, fast and reliable homogenization and lysis of ... researchers to prepare samples for analysis faster, minimize cross-contamination, ...
Cached Biology Technology:SyntheMed Receives CE Mark Approval for REPEL-GYN™ 2Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 2Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 3Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 4MO BIO Laboratories, Inc. Launches PowerLyzer(TM) 24 Bench Top Bead-Based Homogenizer 2
(Date:4/17/2014)... Singh Thursday as a "Champion of Change" for ... in the residential, commercial and industrial sectors. , ... and Computer Engineering and director of Clemson,s Center ... leading the charge across the country to create ... driving policy changes at the local level to ...
(Date:4/17/2014)... in France have hit on a novel method ... the correct and most effective treatment possible., Kidney ... western and developing world. If left untreated, apart ... renal failure and other complications. In many patients ... Clearly a more effective pathological approach to diagnosis ...
(Date:4/17/2014)... BLOOMINGTON, Ind. -- Indiana University researchers have detected new ... with diabetes. This discovery could have far-reaching implications for ... the care of over 25 million Americans. , "We ... the retinas at such early stages," said Ann Elsner, ... Optometry and lead author of the study. "We set ...
Breaking Biology News(10 mins):White House honors Clemson professor as 'Champion of Change' for solar deployment 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... Energy,s Savannah River National Laboratory and the Chernobyl Center,s ... issue of the Health Physics Journal entitled, ... Zone 25 Years After the Accident," (Vol. 101, ... Office of Environmental Management,s (EM) International Program, SRNL and ...
... Energy Department,s laboratories are making headway on two projects ... charges faster, lasts longer, runs more safely, and might ... Lithium batteries are used in a variety of everyday ... battery could also significantly increase the charge capacity of ...
... named 13 U.S. Department of Energy (DOE) researchers as ... and Engineers (PECASE). This is the highest honor bestowed ... who are early in their independent research careers. The ... a variety of fields - from research to help ...
Cached Biology News:Journal focuses on Savannah River National Labratory, Chernobyl Laboratory collaboration 2Journal focuses on Savannah River National Labratory, Chernobyl Laboratory collaboration 3National labs leading charge on building better batteries 2US Department of Energy PECASE recipients 2US Department of Energy PECASE recipients 3US Department of Energy PECASE recipients 4
... MBPK Antibody - Red, 20X ... containing MBPK antibody at 20X concentration ... fluorescence polarization assays. ... KinEASE™ 645nm FarRed fluorescence polarization assays. ...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
CD69/CD3 50 tests...
Biology Products: